FUBP1 and osteosarcoma: Overexpression of FUBP1 conferred lobaplatin resistance in osteosarcoma, whereas inhibition of FUBP1 using either siRNA or lentivirus‐mediated shRNA sensitized osteosarcoma cells to lobaplatin both in vitro and in vivo.